Supriya Lifescience has informed that Kedar Karmarkar (Din No.:06499019) and Bhairav Chokshi (Din No.:03612527), Independent Directors of the Company, has completed their 2 terms of 5 years as Independent Directors on February 1, 2025 and accordingly they will cease to be Directors and Independent Directors of the Company with effect from February 1, 2025. In continuation of Outcome of the Board Meeting dated January 24, 2025, filed on January 24, 2025, the company has informed that Dr. Ganapati Dadasaheb Yadav (DIN: 02235661) and Dr. Sunil Subhash Bhagwat (DIN: 10178976) were appointed as an Additional Directors - Non-Executive, Independent Category, with effect from January 24, 2025. Details as required to be disclosed as per the LODR Regulations read with SEBI’s Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, and Circular No. SEBI/HO/CFD/ CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, are enclosed as Annexure – A.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.00 |
| Cipla | 1211.30 |
| Zydus Lifesciences | 920.00 |
| Lupin | 2316.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: